1135 related articles for article (PubMed ID: 24380394)
21. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
He M; Yokota T
Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
[TBL] [Abstract][Full Text] [Related]
22. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
23. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
24. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ
Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555
[TBL] [Abstract][Full Text] [Related]
25. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
Popplewell LJ; Graham IR; Malerba A; Dickson G
Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
[TBL] [Abstract][Full Text] [Related]
26. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
28. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
30. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
[TBL] [Abstract][Full Text] [Related]
31. Design and application of bispecific splice-switching oligonucleotides.
Bestas B; McClorey G; Tedebark U; Moreno PM; Roberts TC; Hammond SM; Smith CI; Wood MJ; Andaloussi SE
Nucleic Acid Ther; 2014 Feb; 24(1):13-24. PubMed ID: 24506779
[TBL] [Abstract][Full Text] [Related]
32. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
Aartsma-Rus A; van Ommen GJ
RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
[TBL] [Abstract][Full Text] [Related]
33. Induced dystrophin exon skipping in human muscle explants.
McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
[TBL] [Abstract][Full Text] [Related]
34. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
[TBL] [Abstract][Full Text] [Related]
35. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
Takeda S
Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
[TBL] [Abstract][Full Text] [Related]
36. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
[TBL] [Abstract][Full Text] [Related]
37. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
Mitrpant C; Fletcher S; Iversen PL; Wilton SD
J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
[TBL] [Abstract][Full Text] [Related]
38. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
Aoki Y; Yokota T; Nagata T; Nakamura A; Tanihata J; Saito T; Duguez SM; Nagaraju K; Hoffman EP; Partridge T; Takeda S
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13763-8. PubMed ID: 22869723
[TBL] [Abstract][Full Text] [Related]
39. Overview on DMD exon skipping.
Aartsma-Rus A
Methods Mol Biol; 2012; 867():97-116. PubMed ID: 22454057
[TBL] [Abstract][Full Text] [Related]
40. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
Niks EH; Aartsma-Rus A
Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
